A landmark study published in Nature on May 27, 2026, unveiled a universal biological clock capable of predicting mortality risk across multiple mammalian species. By analyzing more than 11,000 gene expression profiles, researchers identified molecular signatures that track biological aging rather than chronological age.
“They developed transcriptomic clocks that don’t just estimate age; they measure the progressive loss of cellular function and predict biological decline and mortality risk across mammals,” said Harvard geneticist David Sinclair. More broadly, the discovery reflects a major shift in longevity science: if the past decade was focused on understanding why we age, 2026 may be remembered as the year scientists began measuring and targeting aging itself.
What are the Hallmarks of aging?
Those findings are the basis of a scientific framework that has quietly been shifting the practices of medicine since 2013. Originally published in Cell magazine by Spanish biologist Carlos Lopez-Otin and team, the Hallmarks of Aging defined for the first time the 12 biological drivers of aging, from DNA damage and telomere attrition to the buildup of wandering, dysfunctional, zombified cells and the gradual disintegration of the gut microbiome.
Further refined in 2023 with three additional hallmarks, the Hallmarks framework has emerged as the dominant roadmap for longevity science and practice throughout the globe. The TACO clock, whose workings measure several of these hallmarks simultaneously, is thus the most comprehensive and integrated biological aging tool to date, according to its creators.In simple terms, the TACO clock analyzes patterns of gene activity to estimate biological decline and mortality risk rather than simply calculating chronological age.
Why This Matters
Rather than waiting for age-related diseases to appear, future healthcare may be able to identify biological decline earlier and act before significant damage occurs.
- Earlier detection of biological aging
- More personalized longevity interventions
- Better prediction of future health risks
- New therapies targeting the biology of aging
- Potential improvements in healthspan, not just lifespan
These possibilities are no longer theoretical. Several breakthroughs in 2026 suggest longevity science is already moving toward clinical application.
The drug that resets human cells is now in clinical trials
One of the clearest examples of this shift can be seen in the emergence of therapies designed to directly target the biological mechanisms of aging.
On January 28, Life Biosciences of Boston, co-founded by Harvard geneticist David Sinclair, gained FDA approval for the first-ever human trial of a partial epigenetic reprogramming drug. ER-100 employs gene therapy to directly inject three of the four Yamanaka factors, the sets of genes that can reset a cell’s biological age, into the eyes of patients with glaucoma and optic nerve disease. “It’s a transformational day for science in general,” said Life Bio CEO Jerry McLaughlin. The trial is the first-ever real-world attempt to reverse cellular aging in people, not merely slow it down.
Watch: David Sinclair on the Most Surprising Longevity Discoveries
As cellular reprogramming enters human trials, David Sinclair reflects on the breakthroughs that turned age reversal from a laboratory concept into a clinical reality.
A Senolytic Compound Restores Tissue Repair in Aging Skin
Following this, another well-publicized aging drug story came out weeks later. On May 19, a team at Boston University announced to the world that a compound called ABT-263, applied topically to the skin of aged mice, caused a striking removal of “senescent zombie cells” that accumulated with age and dramatically improved healing of wounds. The pre-aged mice treated with the topical agent achieved 80% wound closure by the 24th day, compared to only 56% in untreated controls. “These cells fuel inflammation and prevent normal tissue regrowth, and so it’s no surprise that their ablation rejuvenates their environment,” said coauthor David Sharp; the same team reported in a related publication this month of 2026 that delivery of the same compound as a dressing caused a similar effect in diabetic mice. The science of senolytic drugs, which tend to kill dysfunctional aged cells, is speeding from lab mice to machines and patients faster than many had thought possible.
From laboratory to clinic: Bangkok symposium as proof of translation
In fact, clinicians across the Asian continent were already beginning to utilize the hallmarks model even before the flood of papers for this year:. In February 2026, doctors and longevity experts convened in Bangkok for the Practical Anti-Aging Symposium, one of the most obvious indicators that a scientific roadmap laid out in an academic paper from 2013 has more than just been put into guidelines: it has been turned into a clinical blueprint. ” longevity medicine is shifting toward earlier detection of aging-related risk factors,” explained Dr. Tanaporn Eiamprapai, Medical Director of Bangkok’s R3 Life Wellness Center, who participated in the colloquium. Her clinic now provides testing for telomere length, mitochondrial function analysis, and stem cell interventions, with each in mind as an individual hallmark. The Bangkok symposium demonstrated how some longevity clinics are already applying hallmark-based approaches years before broader regulatory adoption.
Longevity therapies moving toward the clinic
| Therapy Type | Target Hallmark(s) | Development Stage (2026) | Potential Benefit |
| Senolytics | Cellular Senescence | Human clinical trials | Improved tissue function |
| Rapalogs | Nutrient Sensing | Multiple human studies | Extended healthspan |
| Partial Reprogramming | Epigenetic Alterations | Early clinical translation | Cellular rejuvenation |
| Mitochondrial Drugs | Mitochondrial Dysfunction | Phase I/II studies | Energy restoration |
| Stem Cell Rejuvenation | Stem Cell Exhaustion | Translational stage | Tissue regeneration |
| Microbiome Therapeutics | Dysbiosis | Clinical deployment | Reduced inflammation |
The Companies Competing to Transform Longevity Medicine
Life Biosciences is not on this journey by itself. Altos Labs, backed by Amazon founder Jeff Bezos, has received billions of dollars in funding to develop its own cellular reprogramming platform.
Retro Biosciences, backed by OpenAI’s Sam Altman, is developing a similar approach. Concurrently, metformin, the world’s most widely used drug for diabetes, is being studied in the TAME trial, the world’s largest clinical trial ever conducted for biological aging. The results of this trial are expected to be published by 2027. Preparation of NAD+ precursor supplements are now widely available and continue to be investigated for their potential role in supporting mitochondrial health. And senolytics, including quercetin and fisetin, are moving into human trials at centers such as the Mayo Clinic. All of these concurrent tracks are joined up by the framework of the Hallmarks of Aging, a shared language in a field that, only ten years ago, had very few.
Is Aging a Disease? Science and Regulation Still Disagree
Not all scientists agree on how quickly longevity medicine is progressing or how aging itself should be defined. The FDA in particular does not see aging as a disease, a regulatory fact that “makes it difficult for any one company to determine the true health benefits of a sole aging intervention,” as Ryan says. It is not just the definition of aging that is debated: in April 2024, Lpez Otn and Kroemer even argued for the inclusion of psychosocial factors—loneliness, chronic stress, and economic hardship as a 13th hallmark of aging, contending that “we cannot dissociate the biological clocks our living body manages from the social clocks we are subject to.” “The hallmarks are not just molecular,” continue the scientists. While detractors say that the longevity medicine field is progressing ahead of the evidence, proponents say the evidence is outstripping the science.
Looking ahead: the Hallmarks of aging symposium, October 2026
Coming up is another key ‘Hallmarks’ meeting in October when Cell Press, the publisher of the journal that first came up with the hallmarks, will gather the global elite of aging scientists in Seville, Spain, from 4 to 6 October for a ‘Hallmarks of Aging’ symposium. The hallmarks keynote speaker, Luigi Ferrucci, Scientific Director of the US National Institute on Aging, is widely anticipated to unveil new biomarker data from the NIA’s classic longitudinal studies. It is expected that this meeting will display the first cross-species data to emerge from the TACO clock in humans and perhaps precipitate a redefinition of the hallmarks. Abstract submission closed June 5. The field is moving in real time.
Conclusion
Aging is no longer just a subject of research. It is a target. If the last decade was about understanding the biology of aging, 2026 may be remembered as the year scientists began measuring and targeting it. From the first FDA-approved human reprogramming trial to a universal mortality clock published in Nature, the science of the Hallmarks of Aging has left the laboratory for good. The only question that remains is the one Sogevity has always asked: What will you do with the time science is giving back to you?
